ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / APMD / news
DSGN (33) SGMT (41) WVE (22) ABUS (18) ⌘ Pro Terminal →

Why APMD Stock dropped -6.10% Today — RQD Quant Desk Flash

$15.40 -6.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.20

Apnimed Inc. (APMD) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $682.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is APMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Apnimed Inc. (NASDAQ: APMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $15.40 (-6.10% 1D, market cap $682.7M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, APMD ranks #402 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does APMD compare to DSGN and SGMT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APMD carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DSGN (Design Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -32.1%, cap $668.4M) and SGMT (Sagimet Biosciences Inc. (Series A)) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $699.7M). Among the 5-stock peer group, APMD leads on earnings multiple (N/A) while DSGN leads on capital efficiency (-32.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APMD?
▼

Per APMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001745648), Apnimed Inc. generated $30.6M in revenue, $0 in net income, and $0 in free cash flow against $72.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.20 (-1.29%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 62.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
$37 Bull$14 Base$11 Bear
📬 FREE APMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APMD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY APMD SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 62.5% FCF Margin ($19.1M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$17.83+3.8% Next Q
Q2 (-2Q)
48
Grade D$18.51+5.3% Next Q
Q3 (-1Q)
46
Grade D$19.49-21% Next Q
Current
43
Grade D-$15.40-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APMD currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($22.53) and Max Pain ($16.17) forces dealer call-delta covering toward $37.05.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “APMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why APMD Stock dropped -6.10% Today — RQD Quant Desk Flash

Apnimed Inc. (APMD) dropped -6.10% to $15.40, trading at 2% of its 52-week range ($16.12 – $35.29). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($16.12 – $35.29) with RSI-14 at 37.2 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $15.40 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $19.1M annual free cash flow.
Live APMD Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APMD)

  • ✓Walkthrough of APMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
APMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.40%🛡️ HOLDING TREND SUPPORT
2026-11-03O $17.34H $17.34L $15.40C $15.40VOL 466.5K
RES: $18.53SUP: $15.14SMA50: $22.53SMA200: $23.92
$36.68$30.91$25.15$19.38$13.61RES $18.53SUP $15.14$15.402026-07-312026-08-242026-09-172026-10-092026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APMD Butterfly Map → + Track APMD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on APMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for APMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APMD)

Health Care Rank #402 of 1015 ⚔️ DSGN vs APMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APMD vs. DSGN, SGMT, WVE, ABUS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Apnimed Inc. (APMD) ranks #402 by composite RQD confidence (43/100, grade D-) and #397 by equity capitalization ($682.7M). Within this direct 5-issuer industry benchmark cohort, APMD leads on earnings valuation at N/A trailing P/E, while DSGN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. APMD currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
APMD ACTIVE
Apnimed Inc.
D- 43/100 — — — -6.10% $682.7M Benchmark Subject
DSGN
Design Therapeutics Inc.
E 33/100 — — -32.1% -4.96% $668.4M /dsgn-vs-apmd →
SGMT
Sagimet Biosciences Inc. (Series A)
D- 41/100 — — -35.0% -2.32% $699.7M /sgmt-vs-apmd →
WVE
Wave Life Sciences Inc.
E 22/100 — — -35.0% -1.95% $708.1M /wve-vs-apmd →
ABUS
Arbutus Biopharma Corporation
E 18/100 — — -35.0% -4.99% $645.3M /abus-vs-apmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001745648 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apnimed Inc. (APMD) reported GAAP revenue of $30.6M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, APMD closed FY2025 with $72.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $30.6M $0 — — $72.9M $0

3. APMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Apnimed Inc. (NASDAQ: APMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $15.40 (-6.10% 1D, market cap $682.7M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, APMD ranks #402 in composite RQD confidence.

How does APMD compare to DSGN and SGMT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APMD carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DSGN (Design Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -32.1%, cap $668.4M) and SGMT (Sagimet Biosciences Inc. (Series A)) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $699.7M). Among the 5-stock peer group, APMD leads on earnings multiple (N/A) while DSGN leads on capital efficiency (-32.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APMD?

Per APMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001745648), Apnimed Inc. generated $30.6M in revenue, $0 in net income, and $0 in free cash flow against $72.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APMD trading relative to its 50-day, 200-day, and 52-week technical levels?

APMD last traded at $15.40 (-6.10% on volume of 530,968 shares), positioning the stock -31.65% below its 50-day simple moving average ($22.53) and -35.62% below its 200-day simple moving average ($23.92). Across its 52-week range of $16.12 to $35.29, APMD sits at the 0.0% percentile with a 14-day RSI of 37.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.47 to $17.33).

Direct Sub-Reports: APMD RQD Cockpit APMD 12M Forecast APMD Earnings & Move APMD Dividends & DRIP APMD Insiders & 13F APMD Whale Options APMD Profit Sankey APMD News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

APMD — Apnimed Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Apnimed Inc. (APMD) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $15.40 (-6.10% 1D, market capitalization $682.7M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Apnimed Inc. (APMD) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.7B. Per the recent news wire, the company's late-breaking sleep apnea presentations and Phase 3 AD109 data in obstructive sleep apnea are slated for CHEST 2026. — for product sales, customer base, or revenue model details.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Apnimed Inc. (APMD) reported $30.6M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $72.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $16.12 – $35.29 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note that the absence of mapped links means this dossier cannot identify supplier, customer, or partner exposure from the source data.

  • Key Question #1: Can APMD sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $30.6M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is APMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

APMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Apnimed Inc. (APMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to APMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APMD Bull vs. Bear Conversation Board — What's Your Call at $15.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on APMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $21.65 (+32.0%)
📌 Pinned Debate

The forensic balance sheet scores 13/20 with a Piotroski F of 6/9, Debt/Equity of 0.5, and $41.9M in cash against $0.0M debt.

Long APMD at $16.40 targeting $21.65. The forensic balance sheet scores 13/20 with a Piotroski F of 6/9, Debt/Equity of 0.5, and $41.9M in cash against $0.0M debt.. Institutional whale score is 3/20 and the risk/reward vs. the $16.12 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@ForensicBear Shorting a 3/20 institutional whale-flow stock at $16.40 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $13.78 (-16.0%)
Spot @ $16.40

The RQD cash engine scores 10/20 with 0% ROIC and 0% FCF yield, while whale flow scores only 4/20.

Here is the bear case nobody on the bull side wants to address on APMD: The RQD cash engine scores 10/20 with 0% ROIC and 0% FCF yield, while whale flow scores only 4/20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%